DNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks clear upward momentum, has weak financial performance, and no significant positive catalysts to support a compelling entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 40.61, and moving averages are converging, showing no clear trend. The stock is trading near support levels (S1: 8.062), with resistance at 10.087.
Analysts maintain a Buy rating with a price target of $12, suggesting potential upside. The company has shown improvement in net income and EPS YoY.
Revenue dropped significantly by -56.39% YoY in Q3 2025, and gross margin declined by -22.52% YoY. The stock is down -5.99% in regular market trading, and technical indicators suggest bearish momentum. No recent congress trading or influential figure activity.
In Q3 2025, revenue dropped to $38.84M (-56.39% YoY). Net income improved to -$80.76M (+43.18% YoY), and EPS increased to -1.45 (+34.26% YoY). Gross margin declined to 67.04% (-22.52% YoY).
TD Cowen maintains a Buy rating but lowered the price target to $12 from $14. Analysts are optimistic about multi-year growth frameworks but emphasize the importance of 2026 guidance updates for sector recovery.
